| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DXCM | Common Stock | Other | $0 | -18.8K | -53.17% | $0.00 | 16.5K | Jun 3, 2021 | Direct | F1, F2 |
| transaction | DXCM | Common Stock | Other | $0 | +18.8K | $0.00 | 18.8K | Jun 3, 2021 | by Trust | F1, F3 | |
| transaction | DXCM | Common Stock | Sale | -$897K | -2.39K | -12.74% | $375.00 | 16.4K | Jun 3, 2021 | by Trust | F3, F4 |
| Id | Content |
|---|---|
| F1 | Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
| F2 | Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |
| F3 | Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
| F4 | On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. |
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development